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A series of potent, selective inhibitors of protein kinase C has been derived from the structural ead provided by the microbial broth products, 
staurosporine and K252a. Our inhibitors block PCK in intact cells (platelets and T cells), and prevent he proliferation of mononuclear cells in 
response to interleukin 2 (IL2). 
Protein kinase C; Selective inhibition; Platelet; T cell; Interleukin 2 
1. INTRODUCTION 
The isoenzyme family, protein kinase C (PKC) [l], 
has been implicated as a key element in many signal 
transduction processes [2]. Involvement of PKC has 
been inferred by the use of specific activators of the en- 
zyme such as phorbol esters, but clarification of its 
precise role in cell functions has been hampered by the 
lack of potent selective inhibitors. This communication 
describes the derivation of a series of such inhibitors 
based on the structure of the microbial metabolites, 
staurosporine [3] and K252a [4], which are potent but 
non-selective PKC inhibitors. Both staurosporine and 
K252a have a flat, polyaromatic aglycone which itself 
inhibits PKC. Modification of the sugar moieties has 
resulted in some modulation of potency and selectivity 
15-71. 
raphy [15] were added to a reaction cocktail (90~1) containing 
0.22 mg/ml lysine-rich histone (type IIIs, Sigma), 0.56 mM CaClr, 
44 pug/ml phosphatidylserine, inhibitor in 10 ,~l DMSO and 11 PM 
[y-“P]ATP in 25 mM Tris-HCl, 5 mM Mg(NO& buffer, pH 7.5 
[16]. After 10 min incubation at 3O”C, the reaction was stopped by 
addition of 1 ml ice-cold 10% trichloroacetic acid. Acid-precipitable 
protein was collected on glass-fibre discs and incorporated radioac- 
tivity determined by liquid scintillation spectrometry. 
2.2. Inhibition of PKA in vitro 
10 ~1 bovine heart PKA (0.1 mg/ml; Sigma) were added to a reac- 
tion cocktail (90~1) containing 0.67 mg/ml histone (type Vs, Sigma), 
1.1 ,uM CAMP, inhibitor in lop1 DMSO and 11 PM [y-32P]ATP in 
200 mM Tris-HCI, 40 mM MgC12, pH 8.5. After 10 min incubation 
at 37°C the assay procedure thereafter was that described for PKC. 
2.3. Inhibition of Ca’+/calmodulin-dependent protein kinase in vitro 
30 ~1 CalCaM-dependent protein kinase, partially purified from 
We wished to investigate whether activity could be re- 
tained in analogues of the aglycone which did not have 
flat geometries. Compounds were synthesised in which 
a bond in the aglycone had been formally removed and 
an extra carbonyl group introduced into the lactam 
ring. This ensured that, through steric interactions, no 
low-energy conformation could have an indole group 
coplanar with the 5-membered ring. 
rat brains by ion-exchange chromatography [17], were added to a 
reaction cocktail (70 ~1) containing 0.29 fig/ml myosin light chains, 
143 FM CaC12, 14 pg/ml CaM and 14 PM [Y-‘~P]ATP, in 10 mM 
Pipes, 4 mM MgCl2, pH 6.9. The assay procedure thereafter was that 
described for PKC. 
2.4. Inhibition of PKC in platelets 
2. MATERIALS AND METHODS 
2.1. Inhibition of PKC in vitro 
10 pl rat brain PKC, partially purified by ion-exchange chromatog- 
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100 ml blood from a human volunteer were centrifuged at low 
speed (140 x g) to produce platelet-rich plasma. Plasma was then 
spun at higher speed (600 x g) to deposit platelets as a soft pellet 
which was resuspended in 2.5 ml 15 mM Tric-HCl containing 
140 mM NaCl, pH 7.4. Cells were rested at 37°C for 90 min before 
addition of 350 pCi carrier-free [32P]orthophosphate in dilute HCl 
and incubation for a further 60 min. Inhibitors, dissolved in DMSO, 
were added to aliquots of platelet suspension so that the final solvent 
concentration was 1%. Cells were preincubated with inhibitor for 
20 min at 37°C before stimulation with 1 pM TPA for 3 min. The 
reaction was terminated by addition of protein disruption buffer 
followed by boiling for 2 min. Aliquots (30~1) were subjected to 
17.5% SDS/PAGE. Gels were exposed to Fuji-RX X-ray film for 
24 h at - 80°C. “P incorporation was assessed by densitometric scan- 
ning of the autoradiograph. 
Abbreviations: PKC, protein kinase C; PKA, c-AMP dependent pro- 
tein kinase; TPA, 12-O-tetradecanoylphorbol 13-acetate; PDBu, 
phorbol 12,13-dibutyrate; DMSO, dimethyl sulphoxide; IL2, inter- 
leukin 2; SDS/PAGE, sodium dodecyl sulphate/polyacrylamide g l 
electrophoresis 
2.5. Inhibition of down-regulation of CD3 
Freshly prepared human peripheral blood mononuclear cells were 
treated with inhibitors for 15 min prior to addition of PDBu 
(100 ng/ml). After a further 30 min incubation at 37”C, cells were 
washed with ice-cold phosphate-buffered saline, incubated 1 h at 4°C 
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with anti-CD3 @era-Lab), washed again and incubated with lz51- 
labelled anti-murine immunoglobulin (Amersham International). 
Radiolabelled cells were separated by centrifugation through a 
cushion of silicone/paraffin oils (24: 1, v/v). 
3. RESULTS AND DISCUSSION 
Imide 1 inhibited PKC and was more selective than 
the staurosporine-like compounds (table 1). From com- 
parison of the relative inhibitory potencies of stauro- 
sporine and K252a analogues it seemed likely that the 
basic nitrogen of staurosporine contributes ignificantly 
to its activity. We assumed a common binding mode of 
compound 1 and staurosporine and used a molecular 
graphics approach to design compounds capable of 
utilising the putative amine binding site. Compounds 
2-5 showed improved activity over 1 and were even 
more selective for PKC over CAMP-dependent protein 
kinase (PKA) or Ca/calmodulin-dependent kinase. 
Unlike the amine 2, the isothiourea 3 and the quater- 
nary amine 5, the nitroguanidine 4 is not significantly 
protonated at the pH of the assay and it is possible that 
the large dipole moment of the nitroguanidine group is 
a key property for activity of this compound. 
Each of compounds 1-5 was equiactive against PKCs 
derived from rat brain and human neutrophil (data not 
shown). The lower potency against PKA was confirmed 
with enzyme isolated from various sources (bovine 
heart, rat brain and human neutrophil). The com- 
pounds bind to PKC competitively with ATP; a proper- 
ty shared with staurosporine and K252a [5]. This was 
confirmed directly in the case of compound 3 
(Lineweaver-Burke plot; Ki = 3 nM) and was inferred 
for the other inhibitors from the consistent 6-8-fold 
drop in potency produced by a lo-fold increase in ATP 
concentration (table 1). 
PKC activation in cells is most directly measured by 
pre-labelling human platelets with [ 32P]orthophosphate 
and following the phosphorylation of specific proteins 
after treatment with the PKC activator 12-O-tetra- 
decanoylphorbol 13-acetate (TPA) [8]. Our inhibitors 
dose-dependently antagonised TPA-induced phos- 
Table 1 
Inhibitor 1Cs0 values (,uM) against isolated protein kinases 
Rat brain Bovine heart Rat brain 
protein protein Ca”/calmodulin- 
kinase C kinase A -dependent 
10/M 100,xM 
protein kinase 
ATP ATP 
K252a 0.47 n.d. 0.20 0.30 
Staurosporine 0.01 n.d. 0.12 0.04 
1 0.30 2.6 16 >lOO 
2 0.08 0.58 5.1 15 
3 0.01 0.08 1.5 17 
4 0.03 0.20 3.3 14 
5 0.09 n.d. >20 >lOO 
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Fig. 1. Structures of PKC inhibitors. 
phorylation of a 47 kDa protein in intact human 
platelets (see fig.2). The function of this protein is not 
yet established [9], but these experiments provide a 
useful demonstration of the ability of the inhibitors to 
penetrate the cell and prevent PKC-mediated phos- 
phorylation. The higher concentrations of ATP in cells 
[lO,l l] (mM as opposed to 10 PM in the isolated en- 
zyme assay) probably contribute to the reduced potency 
of compounds l-4 in intact cell systems but nevertheless 
abcdef 9 h i j 
Fig.2. Autoradiograph showing the effect of various concentrations 
of compound 2 on TPA-induced P47 phosphorylation. TPA was 
present in lanes (b-j) and solvent (DMSO) in lane (a). The concentra- 
tion of compound 2 in each lane was: a-c, solvent only; d, 100 pM; 
e, 30 pM; f, 10 CM; g, 3 pM; h, 1 pM; i, 0.3 pM; j, 0.1 ,xM. The posi- 
tion of molecular weight markers is indicated in the left-hand lane. 
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Table 2 
Inhibitor I&O values (PM) in cellular systems 
Inhibition of 
TPA-induced P47 
phosphorylation 
in platelets 
Inhibition of 
CD3 down- 
-regulation 
K252a 44 20 
Staurosporine 0.6 0.2 
1 > 100 >lOO 
2 4.4 3.1 
3 0.7 0.5 
4 1.2 2.1 
5 > 100 >lOO 
these compounds display structure/activity relation- 
ships in the platelet system which correlate closely with 
those obtained against he isolated enzyme. The lack of 
activity of the quaternary amine (5) in the platelet 
system may be explained by its inability to cross the cell 
membrane. 
The T cell surface protein complex, CD3, which is 
part of the T cell receptor for antigen is phosphorylated 
on triggering by antigen [12] and by treatment with 
phorbol esters [13]. Phosphorylation at serine-126 is 
associated with down-regulation of CD3 and may be an 
integral part of the T cell activation process [14]. The 
PKC inhibitors described in this report inhibited 
phorbol-induced CD3 down-regulation with potencies 
closely parallel to those observed in the platelet phos- 
phorylation studies (table 2). 
After this demonstration of PKC inhibitory activity 
in cells, the studies were extended to investigate ffects 
on the response to a physiologically relevant agonist. 
The involvement of PKC in IL2 signal transduction is 
unclear. Compounds 2 and 3 do, however, inhibit 
ILZinduced proliferation of human peripheral blood 
mononuclear cells with I&s of 3.2 and 0.8 PM, respec- 
tively. The similarity of these values to those in 47 kDa 
phosphorylation and CD3 down-regulation is consis- 
tent with a role for PKC in this proliferative response to 
IL2. 
The potent, selective inhibitors of protein kinase C 
described in this communication have been shown to 
block enzyme activity in intracellular environments. 
Tools have therefore been generated which will 
facilitate the determination of the physiological impor- 
tance of PKC in the whole range of cellular activation 
processes induced by specific agonists. The possibility 
of using these and related agents for therapeutic in- 
tervention in a wide range of diseases including immune 
disorders, oncology and inflammation will be evaluated 
further in cellular systems and in animal models of the 
diseases. 
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